Claims for Patent: 6,245,766

Summary for Patent: 6,245,766

Title:	Method of treating psychiatric conditions
Abstract:	A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
Inventor(s):	Watsky; Eric J. (Stonington, CT)
Assignee:	Pfizer Inc (New York, NY)
Application Number:	09/216,334
Patent Claims:	1. A method for treating a psychiatric condition or disorder selected from dementia, dementia of the Alzheimer's type, bipolar disorders, mood disorder with depressive features, mood disorder with major depressive-like episode, mood disorder with manic features, mood disorder with mixed features, substance-induced mood disorder and mood disorder not otherwise specified (NOS), panic disorder without agoraphobia, panic disorder with agoraphobia, agorathobia without history of panic disorder, social phobia, postraumatic stress disorder, acute stress disorder, substance-induced anxiety disorder and anxiety disorder not otherwise specified (NOS), dyskinesias and behavioral manifestations of mental retardation, conduct disorder and autistic disorder in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR5## or a pharmaceutically acceptable acid addition salt thereof, wherein Ar is benzoisothiazolyl or an oxide or dioxide thereof each optionally substituted by one fluoro, chloro, trifluoromethyl, methoxy, cyano, nitro or naphthyl optionally substituted by fluoro, chloro, trifluoromethyl, methoxy, cyano or nitro; quinolyl; 6-hydroxy-8-quinolyl; isoquinolyl; quinazolyl; benzothiazolyl; benzothiadiazolyl; benzotriazolyl; benzoxazolyl; benzoxazolonyl; indolyl; indanyl optionally substituted by one or two fluoro, 3-indazolyl optionally substituted by 1-trifluoromethylphenyl; or phthalazinyl; n is 1 or 2; and X and Y together with the phenyl to which they are attached form quinolyl; 2-hydroxyquinolyl; benzothiazolyl; 2-aminobenzothiazolyl; benzoisothiazolyl; indazolyl; 2-hydroxyindazolyl; indolyl; spiro; oxindolyl optionally substituted by one to three of (C.sub.1 -C.sub.3)alkyl, or one of chloro, fluoro or phenyl, said phenyl optionally substituted by one chloro or fluoro; benzoxazolyl; 2-aminobenzoxazolyl; benzoxazolonyl; 2-aminobenzoxazolinyl; benzothiazolonyl; bezoimidazolonyl; or benzotriazolyl. 2. A method according to claim 1, wherein said method is for treating dementia. 3. A method according to claim 2, wherein dementia is selected from the group consisting of vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Creutzfeldt-Jakob disease, substance-induced persisting dementia, dementia due to multiple etiologies and dementia not otherwise specified (NOS). 4. A method according to claim 1, wherein said method is for treating dementia of the Alzheimer's type. 5. A method according to claim 4, wherein dementia of the Alzheimer's type is selected from the group consisting of dementia of the Alzheimer's type with early onset uncomplicated, dementia of the Alzheimer's type with early onset with delusions, dementia of the Alzheimer's type with early onset with depressed mood, dementia of the Alzheimer's type with late onset uncomplicated, dementia of the Alzheimer's type with late onset with delusions and dementia of the Alzheimer's type with late onset with depressed mood. 6. A method according to claim 1, wherein bipolar disorders are selected from the group consisting of bipolar I or II disorder single manic episode, bipolar I or II disorder most recent episode hypomanic, bipolar I or II disorder most recent episode manic, bipolar I or II disorder most recent episode mixed, bipolar I or II disorder most recent episode depressed, cyclothymic disorder and bipolar disorder not otherwise specified (NOS). 7. A method according to claim 6, wherein the current state of bipolar I or II disorder single manic episode, bipolar I or II disorder most recent episode manic, bipolar I or II disorder most recent episode depressed are each characterized as mild, moderate, severe without psychotic features, in partial remission or in full remission. 8. A method according to claim 1, wherein said method is for treating dyskinesias. 9. A method according to claim 8, wherein dyskinesias is selected from drug-induced dyskinesias and neurodegenerative based dyskinesias. 10. A method according to claim 1, wherein said method is for treating behavioral manifestations of mental retardation. 11. A method according to claim 1, wherein mental retardation is selected from the group consisting of mild mental retardation, moderate mental retardation, severe mental retardation, profound mental retardation and mental retardation severity unspecified. 12. A method according to claim 1, wherein said method is for treating behavioral manifestations of conduct disorder. 13. A method according to claim 1, wherein said method is for treating behavioral manifestations of autistic disorder. 14. A method according to claim 1, wherein X and Y together with the phenyl to which they are attached form benzoxazolonyl. 15. A method according to claim 2, wherein Ar is benzoisothiazolyl and n is 1. 16. A method according to claim 1, wherein X and Y together with the phenyl to which they are attached form oxindole optionally substituted by chloro, fluoro or phenyl. 17. A method according to claim 1, wherein Ar is naphthyl and n is 1.